Norman Ng: China’s R and D of PD-1 Immunotherapy Drugs – A Future Hope for Hong Kong?
Norman Ng, Director of Patient Advocacy and Public Affairs at Healthcare Thinkers, shared a post on LinkedIn:
“China’s R&D of PD-1 Immunotherapy Drugs: A Future Hope for Hong Kong?
In recent years, immunotherapy has become an important trend in cancer treatment. Among them, PD-1 (Programmed Death Protein-1) inhibitors, as representatives of immune checkpoint inhibitors, have attracted global attention due to their unique mechanisms and significant efficacy. China has made remarkable progress in this field, with many domestically produced PD-1 drugs emerging, providing cancer patients with more treatment options.
In Hong Kong, the accessibility of PD-1 immunotherapy drugs remains limited. Although several foreign-manufactured PD-1 drugs have been approved in the market, local patients lack sufficient understanding and confidence in Chinese-made PD-1 drugs. In fact, these domestically produced medications may not only be technically competitive but could also offer more reasonable pricing options, alleviating the economic burden on patients.
Introducing Chinese-developed PD-1 drugs into the Hong Kong Hospital Authority’s drug formulary would undoubtedly be a crucial step towards enhancing the equity of medical resources. This would not only benefit more cancer patients but also promote diversity and competitiveness in the local healthcare market.
We should also consider: What profound impacts might this approach have on Hong Kong’s healthcare system?
With small diseases shared through co-payment? How to ensure serious diseases do not lead to poverty?”
More posts featuring Norman Ng.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023